Andrew Williamson

Managing Partner

Andrew Williamson is the Managing Partner of CIC and focuses on technology investments.

Andrew’s background combines R&D, start-up formation and technology investing. Before joining CIC he spent ten years in venture investing at Physic Ventures in San Francisco and True North Venture Partners in Chicago. Before moving into Venture Capital, Andrew led a research group applying High Performance Computing to materials science at Lawrence Livermore National Laboratory.
Andrew has an MA and PhD in Physics from the University of Cambridge and an MBA from the Haas School of Business at the University of California, Berkeley.
Andrew manages CIC's investments in Audio Analytic, AudioTelligence, Origami Energy, PragmatIC, Prowler.io, and Riverlane.

Portfolio

Michael Anstey

Partner

Dr Michael Anstey is a Partner specialising in life science investments.

Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational businesses across North America, Europe, India, and Japan.
Michael was also co-founder of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease.
Prior to BCG, Michael worked at Oxford Capital Partners, where he focused on investing in early stage life science businesses. Michael earned his DPhil in Zoology in the field of neurobiology from the University of Oxford. Michael manages CIC's investments in Bicycle Therapeutics, Congenica, Immutrin, PredictImmune, PolyProx Therapeutics, Sense Bio, Start Codon and Storm Therapeutics.

Portfolio

Carol Cheung

Principal

Carol is a Principal focusing on a range of technology investments.

Prior to joining CIC she worked in a variety of roles at several UK-based early stage tech companies, most recently as Commercial Director of Speechmatics, a Cambridge-based speech recognition start-up. She has a background in financial analysis gained from working in both the UK and Canada. She holds a B. Comm from the University of Toronto, gained an MBA from the University of Cambridge’s Judge Business School and is a CFA charterholder.

Carol manages CIC's investment in Cytora and Geospock.

Portfolio

Ian Jauncey

Operating Partner

Ian is a technology and life sciences investor and entrepreneur. He shares his time between managing his private investment portfolio and assisting CIC companies through critical growth stages.
Following university, Ian was the lead in the world beating team that invented the first optical fibre amplifier, a key enabler for the internet. He has worked in analysis and consultancy, eventually heading up a business division for Siemens AG. Subsequently he initiated tech businesses, acquired others and grew them internationally, leading to multiple exits.
Ian has a BA in Natural Sciences from Oxford, a PhD from Southampton University and is a Chartered Director.

Ian is a Board observer for CIC’s investment in PragmatIC.

Portfolio

Vin Lingathoti

Partner

Vin Lingathoti is a partner at CIC and focuses on technology investments.

Vin is a software engineer by background and has spent over a decade in Silicon Valley working with tech companies. Before joining CIC he led venture investments and acquisitions for Cisco Systems in London and San Jose. At Cisco, he was responsible for investments in Panaseer, Behaviosec, Intersec, 6Wind and Worldsensing. He was also involved in several acquisitions in IoT, Cybersecurity, Datacenter and Enterprise Networking.
Vin has an MBA from The Wharton School, University of Pennsylvania and MS in computer science from University of Potsdam, Germany.
Vin manages CIC's investments in Swim.ai, Imagen and Undo.

Portfolio

Rob Sprawson

Partner and CFO

Rob has more than 25 years of professional and commercial experience providing strategic, financial and corporate finance advice to boards and shareholders, especially in the life science, technology and technology consulting industries.
His previous roles have included CFO of Altacor, an ophthalmic specialty pharmaceutical company, CFO of Warwick Ventures, the Technology Transfer Office of Warwick University, CFO of an AIM listed drug development company and Senior Manager, Corporate Finance at PwC. Rob was also a consultant to Lumora, a molecular diagnostics company spun-out from the University of Cambridge.

He is a Fellow of the Institute of Chartered Accountants in England and Wales.

Robert Tansley

Partner

After seven years working in hospital medicine, Robert worked in development and regulatory roles at Sanofi, the MHRA and Roche. Robert then spent a decade at early stage biotech companies including Arakis (sold to Sosei Inc), founder and CEO at Treague, founding CEO of the University of Copenhagen spin -out Avilex Pharma and part of the founding management team of KalVista (Nasdaq: KALV). Robert qualified in medicine from UCL. He is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an M.Phil in Biostatistics from the University of Cambridge. Robert manages CIC's investments in Abcodia, Carrick Therapeutics, CMR Surgical, Gyroscope, Inivata, Microbiotica and Morphogen -IX.

Portfolio

Michelle Lamprecht

Head of Marketing

Michelle Lamprecht is Head of Marketing. She has 20 years experience of international leadership in strategic marketing across a range of public and privately owned organisations. Prior to CIC Michelle’s previous roles were Group VP Marketing for Sepura and VP Marketing for The Vitec Group Production Solutions division.

Michelle has been a board member for Byte Night (Action for Children), a trustee for Citizen’s Advice and is currently a mentor for the Aspire Foundation.

Michelle has a BSc (Hons) in chemistry from the University of Hertfordshire and a post graduate diploma in marketing from the Chartered Institute of Marketing.

Nick Richards

General Counsel

Nick has over 15 years’ experience advising institutional, corporate and individual investors and the companies they invest into, especially in the technology and life sciences sectors.

Nick qualified into the private equity team of a Magic Circle law firm and has been seconded to the legal department of Goldman Sachs. Prior to joining CIC, Nick was a senior associate at an international law firm.

Nick attended the College of Law and BPP Law School in London and holds an MA in Modern Languages from the University of Oxford. He is a solicitor admitted to practise in England and Wales.

Helen Slack

Executive Assistant

Helen is Executive Assistant to the Life Science Partners, Robert Tansley and Michael Anstey.

Prior to CIC, Helen worked for the NHS and also in Private Healthcare. She has experience of working in management, administrative and clinical roles. Helen has lived in and around Cambridge for most of her life.

Sylwia Szulc

Finance Manager

Sylwia joined CIC as the Finance Manager in 2019.

Sylwia has more than nine years’ accountancy experience, and most recently worked in a busy accountancy practice in Cambridge. She has a BSc in Marketing and Management and an MSc in Marketing from the University of Nicolas Copernicus in Poland. Having grown up in Poland, Sylwia has lived and worked in Cambridge for the last fifteen years. Sylwia is a Member of the Association of Chartered Certified Accountants.

Ellie Terry

Personal Assistant and Office Manager

Ellie is Assistant to the senior team and manages the office.

She has extensive knowledge of Cambridge, having spent over 3 years at Cambridge Enterprise, the University’s commercialisation arm, providing administrative support to the Consultancy Team there. Prior to that Ellie worked in the IT divisions of both Xtravirt Ltd and Savills plc.

Ellie is currently on maternity leave. 

Carissa Tolmie

Executive Assistant

Carissa is Executive Assistant to Vin Lingathoti, Carol Cheung and Michelle Lamprecht. 

Prior to joining CIC, Carissa held senior support roles in various sectors, most recently at Liebherr Great Britain Ltd, where she was Personal Assistant to the General Manager and Regional teams.

Carissa holds an Honours degree in Psychology (specialising in Trauma and Stress) from the University of Johannesburg and a Masters degree in Cognitive and Clinical Neuroscience from Anglia Ruskin University.

 

Victoria Woodward

Head of Business Support

Victoria is Head of Business Support at CIC. As well as managing the administrative team, Victoria coordinates CIC's strategic initiatives and supports the Managing Partner, CFO and Chairman.

Victoria specialises in project management and business development and has almost twenty years’ experience. Prior to CIC, Victoria most recently worked for PA Consulting, OC&C Strategy Consultants and Tyndall AM, which is now Nikko Asset Management.

  • Andrew Williamson

    Managing Partner

  • Michael Anstey

    Partner

  • Carol Cheung

    Principal

  • Ian Jauncey

    Operating Partner

  • Vin Lingathoti

    Partner

  • Rob Sprawson

    Partner and CFO

  • Robert Tansley

    Partner

  • Michelle Lamprecht

    Head of Marketing

  • Nick Richards

    General Counsel

  • Helen Slack

    Executive Assistant

  • Sylwia Szulc

    Finance Manager

  • Ellie Terry

    Personal Assistant and Office Manager

  • Carissa Tolmie

    Executive Assistant

  • Victoria Woodward

    Head of Business Support

Humphrey Battcock

Independent Non-executive Director

Humphrey Battcock was previously co-head of Europe and on the executive committee of Advent International which he joined in 1994. Advent International is one of the world’s leading private equity firms with operations in 10 countries. During his tenure, the firm increased its assets under management from £200 million to £30 billion. Prior to Advent, Humphrey was at Trinity Capital Partners, a UK-focused, technology venture capital firm.

Humphrey is a chartered accountant, with an MBA from London Business School and a Physics degree from Cambridge University.

Humphrey is a member of the Cambridge University Campaign Board and the Downing College Investment Committee. He is a trustee of the Woodland Trust and the Institute for Research in Schools and Sadler’s Wells.

Edward Benthall

Chairman

Edward Benthall has been involved with CIC since its inception. He was Chairman of Cambridge Enterprise Ltd, the University of Cambridge’s commercialisation arm, between 2010 and 2014. Before that he was Chairman of the Campaign Council for the University’s 800th Anniversary Campaign.

Until April 2012, Edward was a Partner of Charterhouse Capital Partners, a leading UK private equity firm. He was a member of the investment team of Charterhouse from 1991 to 2009. During his tenure, Charterhouse raised six funds totalling around €13 billion. In this period Charterhouse realised over 40 investments (made in the same period) achieving a gross internal return rate in excess of 40%.

Edward is a Chartered Accountant and a graduate of Magdalene College, University of Cambridge.

Clive Birch

Independent Non-executive Director

Clive Birch is a retired PricewaterhouseCoopers’ partner. Clive’s role at PricewaterhouseCoopers was that of an auditor and reporting accountant and his industry specialism was in early stage technology and healthcare companies. He was also partner in charge of the Cambridge office for 15 years up to 2010, during which time he was responsible for all aspects of that stand alone business.

The majority of Clive's clients were technology and healthcare companies and, as the partner responsible for them, he not only looked after their audit needs but also helped them deal with the rigors of setting up systems and processes, dealing with outside stakeholders and corporate governance. He was also part of the teams involved in fund raising and listing those clients on various markets.

Prior to moving to Cambridge in 1984, Clive worked for Coopers & Lybrand in Vancouver and London and had exposure to corporate recovery work which gave him hands-on experience of running a number of businesses.

Clive is a Governor of Birkbeck College, part of London University, and is Chairman of Pigeon Land Limited and Pigeon Land 2 Limited.

Ian Leslie

Non-executive Director

Ian Leslie is Director of Information Services at the University of Cambridge.  He was previously Professor of Computer Science at the University with interests in operating systems, distributed systems, and networks.

From 1999 to 2004 he was Head of the Computer Laboratory, and from 2004 to 2009 he was Pro-Vice-Chancellor for Research.  The Pro-Vice-Chancellor role involved co-ordinating research policy, providing academic oversight of the handling of research grants and contracts and interacting with both industrial sponsors and the UK government on research and third stream funding.

Ian has taught courses in communications, introductory hardware design and computer systems modelling.  Since 1985 he has been a Fellow of Christ's College, and until 2002 was Director of Studies in Computer Science at Christ's.

Andy Neely

Non-executive Director

Professor Andy Neely is Pro-Vice-Chancellor: Enterprise and Business Relations at the University of Cambridge and former Head of the Institute for Manufacturing (IfM) and of the Manufacturing and Management Division of Cambridge University Engineering Department. He is a Fellow of Sidney Sussex College and founding director of the Cambridge Service Alliance. He is widely recognised for his work on the servitization of manufacturing, as well as his work on performance measurement and management.

Previously he was a Fellow of Churchill College and has held appointments at Cranfield University, London Business School, Nottingham University and British Aerospace. He was also Deputy Director of AIM Research, the UK’s management research initiative, from 2003 until 2012.

Andy was elected a Fellow of the British Academy of Management in 2007, a Fellow of the Academy of Social Science in 2008 and a Fellow of the European Operations Management Association in 2009.

Rob Sprawson

Partner and CFO

Rob has more than 25 years of professional and commercial experience providing strategic, financial and corporate finance advice to boards and shareholders, especially in the life science, technology and technology consulting industries.
His previous roles have included CFO of Altacor, an ophthalmic specialty pharmaceutical company, CFO of Warwick Ventures, the Technology Transfer Office of Warwick University, CFO of an AIM listed drug development company and Senior Manager, Corporate Finance at PwC. Rob was also a consultant to Lumora, a molecular diagnostics company spun-out from the University of Cambridge.

He is a Fellow of the Institute of Chartered Accountants in England and Wales.

Andrew Williamson

Managing Partner

Andrew Williamson is the Managing Partner of CIC and focuses on technology investments.

Andrew’s background combines R&D, start-up formation and technology investing. Before joining CIC he spent ten years in venture investing at Physic Ventures in San Francisco and True North Venture Partners in Chicago. Before moving into Venture Capital, Andrew led a research group applying High Performance Computing to materials science at Lawrence Livermore National Laboratory.
Andrew has an MA and PhD in Physics from the University of Cambridge and an MBA from the Haas School of Business at the University of California, Berkeley.
Andrew manages CIC's investments in Audio Analytic, AudioTelligence, Origami Energy, PragmatIC, Prowler.io, and Riverlane.

  • Humphrey Battcock

    Independent Non-executive Director

  • Edward Benthall

    Chairman

  • Clive Birch

    Independent Non-executive Director

  • Ian Leslie

    Non-executive Director

  • Andy Neely

    Non-executive Director

  • Rob Sprawson

    Partner and CFO

  • Andrew Williamson

    Managing Partner

David Braben

Member of the Advisory Panel

Dr David Braben OBE is the CEO of AIM quoted Frontier Developments plc, a major games developer and publisher headquartered on the Science Park in Cambridge that he founded in 1994.

David has been in the games industry for over 35 years having studied Natural Sciences at Jesus College, Cambridge, specialising in Electrical Science in his final year, before going on to study Computer Science. David is a BAFTA Fellow (one of only 96 ever awarded), is a Fellow of the Royal Academy fof Engineering, was a co-founder and still a Director/Trustee of the Raspberry Pi Foundation and a Fellow of the Institute of Engineering and Technology. David is an active investor in technology companies.

Charles Cotton

Chairman of the Advisory Panel

Charles Cotton is Founder and Chairman of Cambridge Phenomenon International Limited. He co-authored “The Cambridge Phenomenon 50 Years of Innovation and Enterprise” and  “The Cambridge Phenomenon: Global Impact”. He is a director of AIM quoted Frontier Developments Plc, Solarflare Inc, XMOS Limited, Cambridge Enterprise Limited and is a member of its Investment Committees, Deputy Chairman of Cambridge Ahead and a member of the Board of Trustees of the American University of Sharjah and AUS Enterprises.

Previously he was a Supervisory Board member of Euronext Amsterdam listed Tele Atlas which was sold to TomTom for $4.3 billion in 2008, Executive Chairman of NASDAQ listed GlobespanVirata Inc and Chief Executive Officer of Virata Corp which he took public on NASDAQ in 1999 and acheived a market capitalisiation, at its peak, of more than $5 billion. Prior to that he was President of Thermal Scientific Inc and a Director of London Stock Exchange listed Thermal Scientific. Charles' engagement in high technology dates back to 1983 when he was Sales and Marketing Director at Sinclair Research Limited. After graduating, Charles worked in the automotive industry at British Leyland and Ford.

He holds a BA Hons in Physics from the University of Oxford, is a Fellow of the Institute of Physics and a Fellow of the Royal Society of Arts.

Sir Richard Friend

Member of the Advisory Panel

Professor Sir Richard Friend FRS holds the Cavendish Professorship of Physics at the University of Cambridge. His research encompasses the physics, materials science and engineering of semiconductor devices made with carbon-based semiconductors, particularly polymers. His research advances have shown that carbon-based semiconductors have significant applications in LEDs, solar cells, lasers, and electronics. These have been developed and exploited through a number of spin-off companies.  His current research interests are directed to novel schemes – including ideas inspired by recent insights into nature’s light harvesting – that seek to improve the performance and cost of solar cells.

Sir Richard is a Fellow of the Royal Society and of the Royal Academy of Engineering, and a Foreign Member of the US National Academy of Engineering.  He has received many international awards for his research, including Laureate of the Millennium Prize for Technology (2010), the Harvey Prize of the Israel Institute of Technology (2011) and the von Hippel Award of the Materials Research Society (2015). He was knighted for "Services to Physics" in the Queen's Birthday Honours List, 2003.

John Lee

Member of the Advisory Panel

John Lee is currently Chief Financial Officer of DisplayLink Corp, a market leading USB graphics software and hardware business.  He has been actively involved for many years in the Cambridge technology scene and has been Chief Financial Officer and/or an investor in a number of start-ups, many of which have resulted in successful exits or IPOs.  

Prior to his role at DisplayLink Corp, John was CEO of Velocix, a leading provider of content delivery network solutions which was sold to Alcatel-Lucent and, prior to that he was Chief Financial Officer of a number of early-stage technology based businesses.

For the past eight years John has been Chairman of the Cambridge Enterprise's Investment Committee, which currently manages assets of circa £50 million and which has had a successful track record of both investment and exit over this period.

Ruth March

Member of the Advisory Panel

Ruth March is Senior Vice President of AstraZeneca’s Precision Medicine and Genomics function. Her leadership in precision medicine led to the regulatory approval and launch of 25 new diagnostics linked to four of AstraZeneca’s precision medicines in Oncology and Inflammation.

As the member of the Innovative Medicines and Early Development leadership team responsible for patient selection, Ruth has driven the adoption of innovative precision medicine approaches by 90% of AstraZeneca’s clinical portfolio. These include the first therapeutic label based on circulating tumour DNA, the first companion diagnostic for complex laboratory testing, and the first point of care diagnostic linked to respiratory disease treatment.

Ruth leads the corporate Genomics Initiative, which aims to analyse two million genomes by 2026 to discover rare variants that underlie common disease. With 10 academic and industrial partners, the Centre for Genomics Research publishes award-winning studies at international meetings and in high impact journals.

Ruth serves as a member of Definiens’ Supervisory Board, the National Genomics Board and other advisory boards in genomics and digital health. Her academic career in the genetics of autoimmune disease was centred in London and Oxford.

Jonathan Milner

Member of the Advisory Panel

Jonathan Milner, co-founder and currently Deputy Chairman of Abcam plc, is an experienced entrepreneur and investor and is passionate about supporting UK healthcare and high-tech start-ups.  He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on AIM.

Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath University.  From 1992–95, he was a post-doctoral researcher at Bath, following which he worked at the University of Cambridge in the laboratory of Professor Tony Kouzarides researching the molecular basis of breast cancer.  He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Kouzarides.

Jonathan is currently Chairman of Axol Bioscience, Camallergy Limited, Definigen Limited and PhoreMost Limited and a non-executive director of Horizon Discovery, Syndicate Room Limited, Repositive Limited, Elpis Biomedical Limited, Shift Biosciencs Limited and HealX Limited.  He also sits on the advisory board of Desktop Genetics Ltd.

Sir Keith Peters

Member of the Advisory Panel

Sir Keith Peters’ research has been on elucidation of immunological mechanisms underlying diseases of kidney and blood vessels, which has led to new treatments of these diseases.  He was Regius Professor of Physic at the University of Cambridge from 1987 to 2005, where he was also head of the School of Clinical Medicine.  Under Sir Keith’s leadership, Cambridge has become a major centre for clinical research, complementing the University’s longstanding strengths in basic biomedical science.  He is a fellow of the Royal Society, a founder Fellow of the Academy of Medical Sciences and its second President. 

From 2006-2008 Sir Keith was Interim Director of the MRC’s National Institute for Medical Research and initiated discussions which led to the establishment of the UK Centre for Medical Research and Innovation, the Francis Crick Institute.  Sir Keith is currently a consultant in Clinical Science and Translational Medicine for the Institute.  

From 2005-2016 Sir Keith was a Senior Consultant to the President of Pharmaceuticals R&D at GlaxoSmithKline and has served on the science advisory boards of various biotechnology companies including Cambridge Antibody Technology.

Andy Richards

Member of the Advisory Panel

Dr Andy Richards CBE is an entrepreneur specialising in healthcare and life sciences. He is currently Chairman of Arecor Limited, Congenica Limited, Abcodia Limited and Closed Loop Medicine Limited as well as being a Director of Ieso Digital Health Limited and Owlstone Medical Limited. He was a founder of Chiroscience Group plc and an executive director through its merger with Celltech plc in 1999.

Andy has a track record as a founder, director and active investor in more than 25 innovative healthcare and life science companies, including Vectura and Arakis. He is Chairman of Babraham Bioscience Technologies (the Babraham Campus), a director of Cancer Research Technologies and a member of CRUK. Andy is a graduate of the University of Cambridge with a PhD in Chemistry and is also a founder member of the Cambridge Angels.

John Scarisbrick

Member of the Advisory Panel

Living in Boston, MA, John Scarisbrick is a proven global technology leader with extensive board and advisory experience from high-growth start-ups to the largest enterprises.  John was Chief Executive Officer of CSR PLC between 2005 and 2007 and served on the Board of ARM Holdings plc, the world's leading microprocessor IP company, from 2001 to 2011.  Previously John worked at Texas Instruments for 25 years in variety of leadership roles in France, the UK and the USA.  He was Senior Vice President responsible for all aspects of Texas Instrument’s $5 billion+ world-wide ASP chip business.  He also served as President of TI Europe and earlier led the team that created TI’s Digital Signal Processing business.

John is a non-executive director of Intersec, the high velocity big data analytics company based in Paris.  He has served numerous firms in chair, board-member and advisory roles, including Intrinisty (Austin, TX), Innovative Silicon (Lausanne), ETA Devices (Cambridge, MA), CPS & Ubinetics (Cambridge, UK), SonIM (San Mateo), Netronome (Pittsburgh), Plessey, Samsung and Inphi (Santa Clara).

William Tunstall-Pedoe

Member of the Advisory Panel

William Tunstall-Pedoe was the founder of Cambridge start-up Evi (formerly True Knowledge), a company which has deep technology around understanding natural language and automatically answering questions on any topic. Following its acquisition, the technology became an integral part of Amazon’s Alexa and William held a senior role in the team that defined, built and launched Amazon Echo working with hundreds of scientists and engineers. Evi is now the Cambridge subsidiary of Amazon, employing hundreds of scientists and engineers locally from multiple projects including Alexa and Prime Air.

William is now an active angel investor and fellow of the Creative Destruction Lab, a Toronto based incubator for AI start-ups where he helps many tens of early stage machine learning businesses.

William has a first class honours degree, studying Computer Science at Churchill College, Cambridge. Less serious projects include a commercial chess-playing program, the first and only software which can solve and explain cryptic crossword clues and the AI anagram-generating software which was used by Dan Brown to create the anagrams that were integral to the plot of the Da Vinci Code book and movie.

Sir Gregory Winter

Member of the Advisory Panel

Sir Gregory Winter is Master of Trinity College, Cambridge and a Fellow of the Royal Society.  He is best known for his research and inventions relating to therapeutic antibodies made at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge.

Sir Greg has founded three biotech companies based on his inventions: Cambridge Antibody Technology in 1989 (bought by AstraZeneca), Domantis in 2000 (bought by GSK) and Bicycle Therapeutics in 2009.

  • David Braben

    Member of the Advisory Panel

  • Charles Cotton

    Chairman of the Advisory Panel

  • Sir Richard Friend

    Member of the Advisory Panel

  • John Lee

    Member of the Advisory Panel

  • Ruth March

    Member of the Advisory Panel

  • Jonathan Milner

    Member of the Advisory Panel

  • Sir Keith Peters

    Member of the Advisory Panel

  • Andy Richards

    Member of the Advisory Panel

  • John Scarisbrick

    Member of the Advisory Panel

  • William Tunstall-Pedoe

    Member of the Advisory Panel

  • Sir Gregory Winter

    Member of the Advisory Panel